Compositions and methods for reducing neointima formation
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorsShiyou Chen, Rui Tang
Life of this patent
Estimating the term…
Abstract
Compositions, devices, grafts and methods for reducing or preventing anti-neointima following cardiovascular injuries and interventions are disclosed. The compositions, devices, and grafts typically include an effective amount of a CTP synthase 1 inhibitor to reduce proliferation of vascular smooth muscle cells, without substantial reducing the proliferation of endothelial cells. Methods of reducing neointima formation, accelerating re-endothelialization, and reducing restenosis in a subject using the compositions, devices, and grafts are also disclosed.
Claims20
A method of reducing proliferation of vascular smooth muscle cells or reducing neointima formation in a subject comprising
- administering to the subject cytidine in combination with a nucleoside analog that inhibits cytidine-5′-triphosphate synthase 1 (CTPS1),
- wherein the combination of cytidine and the nucleoside analog are administered to the subject in an effective amount to reduce proliferation of vascular smooth muscle cells (VSMC) in the subject to a greater degree than the combination reduces proliferation of endothelial cells (EC) in the subject.
A method of reducing proliferation of vascular smooth muscle cells or reducing neointima formation in a subject comprising
- administering to the subject cytidine in combination with the nucleotide analog, cyclopentenyl cytosine (CPEC),
- wherein the combination of the CPEC and the cytidine are administered to the subject in an effective amount to reduce proliferation of vascular smooth muscle cells (VSMC) in the subject to a greater degree than the combination reduces proliferation of endothelial cells (EC) in the subject,
- wherein the CPEC is administered by implanting a medical device comprising the nucleotide analog into the subject.
Dependencies are inferred from the claim text.